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The central dialysis fluid delivery system (CDDS) simplifies the maintenance and supervision involved by enabling
the combined management of dialysis fluid for multiple persons, preparation of cleaning and antiseptic solutions,
and delivery of these to each patient monitor. The CDDS has been used exclusively in Japan since 1960s.
Approximately 88 % of dialysis machines are patient monitors with CDDS. It is a cost-effective, laborsaving,
time-tested system with good microbial safety, which has been used for 45 years. In many countries, especially
in Asia, the number of end-stage renal disease (ESRD) patients is increasing. The CDDS will contribute to such
emerging situations with its easy handling and economic advantages.
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It is widely known that the survival rate of Japanese
hemodialysis patients is the highest in the world [1].
This is mainly due to the development of dialysis and
blood purification devices and development of the dialysis
system. Cooperation among academic societies, clinical
engineering technologists, and industries has also played a
significant role. The introduction of the central dialysis
fluid delivery system (CDDS) in the 1960s enabled the
provision of stable dialysis conditions for all patients,
which made a marked contribution to the field of dialysis.
In comparison to single-patient dialysis fluid delivery
system (SPDDS), the central dialysis fluid delivery sys-
tem (CDDS) simplifies the maintenance and supervision
involved by enabling the combined management of dia-
lysis fluid for multiple persons, preparation of cleaning
and antiseptic solutions, and delivery of these to each
patient monitor. Reliability is required in CDDS systems,
as a single abnormality can affect multiple patients
negatively. In Japan, CDDS has evolved from more than
45 years of experience. In many countries, especially in
Asia, the number of end-stage renal disease (ESRD) pa-
tients is increasing [2]. CDDS will contribute to such* Correspondence: h-kawanishi@tsuchiya-hp.jp
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nomic advantages.History of clinical hemodialysis and development
of CDDS
Willem Kolff developed the first successful dialysis treat-
ment. Dr. Kolff used a rotating drum kidney to treat a
67-year-old patient who had been admitted to the hos-
pital with acute kidney failure in 1945 [3]. The success
was partially due to the technical improvements in the
actual equipment used for the treatment. Kolff ’s rotating
drum kidney used membranous tubes made from a new
material known as cellophane. As the membranous tubes
passed through the bath, the uremic toxins would pass
into this rinsing liquid using the abovementioned physical
principles. The Kolff-Brigham kidney passed its practical
test under extreme conditions during the Korean War.
Since then, it has been widely used worldwide as the
SPDDS [4].
The developments that began with the Quinton-Scribner
Shunt allowed the long-term treatment of patients with
chronic kidney failure. In the spring of 1960 [5, 6],
Belding Scribner implanted a shunt in the American,
Clyde Shields, in Seattle. Mr. Shields became the first
chronic hemodialysis patient, and the dialysis treatments
allowed him to live an additional 11 years before dying of
cardiac disease in 1971. Dr. Scribner developed the dialysisicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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center was eventually opened and has been operational
since 1967. The Sweden Seattle-CDDS, Sweden Freezer-
patient monitor, and the Kiil dialyzer developed by
Dr. Scribner are used in this dialysis center [8]. This was
the first dialysis center in Japan where the CDDS was
used, and hemodialysis was performed 24 h a day, 6 days
a week.
Data from the Japanese society for dialysis therapy
(JSDT) showed that there were only 110 patient monitors
in 50 facilities, and the CDDS was used in 56 % of the
cases in Japan in 1968. By the end of 2014, the number of
patient monitors and dialysis facilities had increased to
130,952 in 4314 facilities, respectively, with 90 % of pa-
tients undergoing treatment using the CDDS [9].Fig. 1 Scheme of the single-patient dialysis fluid delivery system (SPDDS), c
delivery system (CDDS)Dialysis fluid delivery systems
Currently available dialysis fluid delivery systems include
the single-patient dialysis fluid delivery system (SPDDS)
(or individual dialysis fluid delivery system) and central
concentrates delivery systems (CCDS), as well as the
CDDS (Fig. 1) [10, 11].
In SPDDS, the patient monitor contains a dialysis fluid
supply equipment. Presently, it is widely used in countries
other than Japan and is considered as the global standard
for dialysis treatment. Although many models require
separate water treatment equipment, a model that has
this built in is also available. Aside from the advantage
of the relatively free location, SPDDS allows for the
individualization of dialysis fluid composition in order
to meet unique patient needs.entral concentrates delivery systems (CCDS), and central dialysis fluid
Table 2 Microbiological Quality Standard for Dialysis Fluids in
Japan, excerpt from reference [14]
Attainment level
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by multiple-patient acid concentrate supply equipment,
and the bicarbonate concentrate (solution B) is intended
to provide individual patient monitor. Different electro-
lyte concentrations of solution A are piped in and chan-
ged according to the patient’s condition. CCDS is easy to
maintain since it purifies in the long pipe in order to
contain the acid in solution A and, possibly, in storage.
The fact that CCDS can be used in the temporary treat-
ment of many patients remains a distinct advantage. It
also allows the additional benefit of variation of the
dialysis fluid compositions and has been used in the
USA and countries such as China, where the number
of patients is increasing.
The CDDS consists of the water treatment and multiple-
patient dialysis fluid supply equipment (MPDFSE), as well
as the patient monitor. Although the ability to supply a
large amount of dialysis fluid is only temporary in CDDS, it
is possible to use many patient monitors [12, 13].
One advantage of the CDDS is that it is usually more
cost effective (Table 1) [10]. Maintenance is simple and
easy and not labor-intensive for the medical staff, if the
system is placed completely. However, one disadvantage
is that malfunction of the central proportioning unit will
simultaneously affect several patients resulting in the
discontinuation of dialysis at the patient station. Also,
central systems do not allow for individualization of the
dialysis fluid compositions to meet the patients’ unique
needs. Additionally, machine dysfunction affects all pa-
tients and there is the constant risk of contamination
with the use of the long dialysis piping. Given these dis-
advantages, CDDS is no longer used in countries other
than Japan.
Why is CDDS used in Japan?
Despite its disadvantages, CDDS has been widely accepted
in Japan primarily because of the need for minimal space
and cost saving options, in order to address the rapid
increase in the number of dialysis patients. Unlike other




• Maintenance is simple and easy, if the system is placed completely
• Labor saving of medical staff
• Possibility of automated operation system
Disadvantages
• Dialysate composition; no permission to individual
• Machine dysfunction affects all patients
• Microbial: risk of long dialysis piping for contaminationsmanufacturers with technical capabilities. Moreover,
the clinical engineering technology system in Japan has
developed specialist maintenance management expertise
of dialysis devices.
Dialysis fluid purification
One problem that is unique to Japan is the process by
which the CDDS should be guaranteed by manufacturers.
Many parts of the CDDS are not approved as medical de-
vices. Since they are manufactured by different companies,
it is difficult to identify the company that is actually re-
sponsible for the device. Although the endotoxin retentive
filter (ETRF), which is important for water and dialysis
fluid purification control, has been determined as an in-
dustrial standard, there is no currently available standard
for its management and application. This must be deter-
mined according to the degree of purity upstream and
treatment mode.
In order to solve these issues, the JSDT published the
“Standard of microbiological management of fluid for
hemodialysis and related therapies” in 2007 (Table 2)
[14] and the “Standard on the management of endotoxinEndotoxin <0.001 EU/ml (less than detection limit)
Indications for dialysis system based on the quality of dialysis fluids
Standard dialysis fluid
Minimum requirement for dialysis therapy
Ultrapure dialysis fluida
Dialysis fluid for the preparation of online substitution fluid.
Dialysis system for active use of back filtrate
Push and pull HDF system
Internal filtration-enhanced dialysis (IFEHD)
Online-prepared substitution fluid
Online HDF/online hemofiltration
aUltrapure dialysis fluid is desirable for all dialysis modalities
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(Table 3) [15]. These were developed in accordance with
the International Organization for Standardization (ISO)
[16] and elaborates on well management in the CDDS
by incorporating the concept of “validation.”
Validation is a concept that was developed for the as-
surance of system compatibility and product quality and
includes the validation of the manufacturing and quality
control methods (i.e., the system design and equipment
of the manufacturing facility, manufacturing procedure
and processes). Confirmed results must yield acceptable
limits, and this must be documented in writing [17].
CDDS are used in many dialysis facilities, where the
dialysis fluids are prepared through multiple processes
performed by various apparatuses connected in series.
These apparatuses are selected and arranged by each
dialysis facility. In such a manufacturing system, a valid-
ation concept is necessary for process management and
product quality assurance. A dialysis facility functions as aTable 3 Standard on the management of endotoxin retentive
filter (ETRF), excerpt from reference [15]
Definition of ETRFs and required performance
• Endotoxin retentive filters generally refer to the filters used to remove
ET and microorganisms from dialysis fluid for their purification. This ETRF
Management Standard addresses the management of an ETRF installed
immediately before the dialyzer in a bedside dialysis console.
• An ETRF should maintain LRVs of at least 2 for ET and at least 4 for
bacteria to obtain ultrapure dialysis fluid, assuming that the dialysis fluid
before the ETRF maintains its microbiological quality at values for
standard dialysis fluid specified in the JSDT Standard.
Standard for handling ETRFs
• Manufacturers’ instructions for the ETRF installation shall be observed.
• To obtain ultrapure dialysis fluid sample, the dialysis fluid at the inlet of
the ETRF should be maintained within the allowable level for standard
dialysis fluid specified in the JSDT Standard.
Cleaning and disinfection of ETRFs
• Dialysis machines shall be cleaned and disinfected following the
methods recommended by the manufacturer.
• The inside and outside of hollow fibers shall be cleaned and
disinfected during the cleaning and disinfection of ETRFs.
• When cleaning and disinfection methods other than those
recommended by the manufacturer are used, the durability of ETRFs
shall be tested at each facility to confirm their safety.
Duration of ETRF use
• The duration of ETRF use recommended by the manufacturer shall be
observed when the dialysis fluid flowing into the ETRF cannot be
maintained within the allowable levels for standard dialysis fluids as
specified in the JSDT Microbiological Quality Standard for Dialysis Fluids.
• The duration of ETRF use should be determined by the Dialysis
Equipment Safety Management Committee when the standard dialysis
fluid falls within allowable levels.
Monitoring and durability test of ETRFs
• When ETRFs are used under conditions other than those
recommended by the manufacturer, their durability shall be tested at
each facility to confirm their safety.dialysis fluid manufacturing facility and is responsible for
the final quality of the dialysis fluid. Therefore, the person
who is responsible for manufacturing the device, including
the managers of the various processes, must be appointed
for the dialysis fluid purification process in the same man-
ner as those performed in manufacturing facilities. At a
dialysis facility where dialysis fluid is also manufactured,
the following requirements of Table 4 must be established
as validation processes for the dialysis fluid purification
procedure. If the results of comprehensive evaluation of
these processes meet the requirements, the dialysis fluid
preparation system is considered to have been validated.
Previously, there were also the concerns about the
need to emphasize complete purification from the up-
stream of the dialysis fluid supply system to the end of
the downstream flow. The concept of validation assumes
that, because contamination is present, it is important to
construct a system that always remains unaffected by
the contamination downstream, in order to isolate the
degrees of contamination to each area. Figure 2 demon-
strates the concept of sterility in each area on the CDDS
[13]. The concept of preventing pollution by isolating the
degree of contamination to each the individual terminal
area is propagated.
The standard on the management of ETRF
Some basic terms and conditions, such as piping manage-
ment, disinfection methods, and equipment management
that were defined in order to achieve purification of the
dialysis fluid, will eventually depend on the performance
of the ETRF. Currently, newly developed dialysis equip-
ment, such as the online hemodiafiltration (HDF) system,
are secured by being approved as a medical device in a
state where the ETRF is incorporated for purification.
However, the performance of the ETRF that have been
incorporated into other systems is defined by industry
standards. Since it has not been recognized as a medical
instrument, provisions for its use in dialysis equipmentTable 4 The requirement as validation processes for the dialysis
fluid purification procedure
• Intended of quality of purification of dialysis fluid
• Validity of equipment, preparation processes, products, and plan of the
preparation method (system design of apparatuses)
• Confirmation of the designs of the equipment, processes and
preparation methods, and their completion as designed (installation
qualification)
• Confirmation of the utility of the equipment, processes, and methods,
in order to achieve the intended objective (operational qualification)
• Testing of the system under the conditions of actual preparation and
confirmation of the operation of the system as designed (performance
qualification) (periodic evaluation of the quality of supply water, RO
water, and dialysis fluid)
• Guarantee the disinfection of the interior of the system during non-use
periods
Fig. 2 Validation of management for microbial contamination in CDDS
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individual dialysis facilities. In response, the JSDT published
the “Standard on the management of endotoxin retentive
filter for dialysis and related therapies.” Table 3 shows the
excerpt of the final document, which is applicable to its
clinical use [15]. Dialysis fluid flowing into ETRF is as-
sumed to be of the “standard quality” of dialysis fluid
(bacteria <100 CFU/ml, endotoxin <0.050 EU/ml) that
complies with the JSDT standards [14].
Actual management of CDDS
As described, water quality management is the responsibil-
ity of the dialysis equipment safety management committee
of each facility. Therefore, the commission has drafted a
management manual and organized a committee, which
regularly scrutinizes for compliance.
The setting of management target value
CDDS is composed of different purification areas, ex-
tending from the upstream and to the downstream areas
(Fig. 2). Basic management entails determination of the
purification of an area, to ensure the maintenance of an
acceptable level of purification. In order to determine
this, the target quality standards in each area need to beidentified. Reference values for each area do not always
need to be set at the highest levels. According to the
purification status of the facility, the value obtained for
the highest level (e.g., ultrapure quality) of purity in the
final dialysis fluid is determined.Determination of management and the confirmation
methods
Based of the state of purification of each area, the manage-
ment (purification and disinfection methods, frequency
of replacement of the ETRF) and verification (collection,
measurement, and frequency of ET and microbial level
determination) methods need to be determined.Measures of the region exceeds the reference value
The purifying measures are necessary if the measured
value of the areas reaches the action level of the reference
value. The action level is set according to the quality
condition of each facility and is typically set at 50 % of
the maximum allowable level, except for endotoxin
levels in ultrapure dialysis fluid [14]. In this case, the
purification and disinfection methods and quality of
the reverse osmosis (RO) membrane and ETRF are
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the reference value.
Judgment of the treating continuation propriety
Even if each area is unable to secure the reference
values, the final dialysis fluid that reached the reference
level values needs to be identified, in order to continue
treatment. However, if the final dialysis fluid is below the
reference level, consideration should be given to changing
the way dialysis is conducted (i.e., stopping the use of the
super high-flux dialyzer by the dialysis equipment safety
management committee).
Further installation, purification, and disinfection
methods, with respect to its duration of use, were deter-
mined according to the manufacturer’s recommendations.
If each facility decides to change the purification/disinfec-
tion methods and the use periods, the dialysis equipment
safety management committee in each facility were re-
sponsible for addressing these issues.
Clinical engineering technologists system
Factors that affect the quality of CDDS maintenance in
Japan include clinical the engineering technology systems
that maintain these dialysis system using key operations.
This is a national qualification that combines both medi-
cine and engineering based on the “clinical engineering
technologists act,” which came into effect in 1987. Among
the 2300 clinical engineering technologists who obtain this
qualification yearly, more than 80 % are involved in blood
purification field.Fig. 3 Flowchart of newly design of CDDS used to achieve fluid purificatioOutline of the newly development of CDDS
Figure 3 describes the processes used by the CDDS to
achieve dialysis fluid purification in a flow chart [18–20].
The source water (main tap water is generally used) is
taken up into the water treatment system and prepro-
cessed through the water softener and activated carbon
adsorption filter. This water is then purified into dialysis
water using a RO module, which is almost completely
free of leaks with a sodium chloride blocking rate of
over 99.5 %.
The dialysis water then accumulates in the dialysis
water tank. In order to prevent cross-contamination of
the dialysis water, water is removed from each line at the
startup of the RO equipment. Any remaining water is
expelled when the equipment is stopped. Dialysis water
is cycled to the RO module while the equipment is in
operation, even when purification is not occurring, in
order to prevent water from pooling inside the equip-
ment. With regard to the dialysis water supply lines, an
ETRF is placed at the re-entry mouth of the dialysis
water tank as a looped pipe, in order to provide circula-
tion to the dialysis water tank, countering the presence
of contaminants inside the pipes and preventing cross-
contamination.
The powdered acid concentrate (solution A) and bicar-
bonate concentrate (solution B) are used to adjust the
dialysis fluid. In the CDDS, a powder-mixing device was
used to dissolve powder A (acid concentrate dry) and
powder B (bicarbonate concentrate dry) in the dialysis
water, which was then supplied with the dialysis water ton
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fluid to each patient monitor. The pipe connecting the
MPDFSE to each patient monitor also has a looped circu-
lation pump in place. This prevents cross-contamination
by eliminating dead-end pipes and causing dialysis fluid to
circulate back, if the flow rate goes above a set level,
preventing water accumulation. ETRF are also placed
immediately after the dialysis fluid inlet of each patient
monitor and looped dialysis fluid pipe, as well as imme-
diately before the dialyzer. When each patient monitor
is started, displacement washing occurs with the purified
dialysis fluid.
Basic disinfection and cleaning method
After the hemodialysis treatment of the day is completed,
all the patient monitors are cleaned, according to a stand-
ard procedure, using a sodium hypochlorite solution,
which is adjusted to within 200–500 ppm by the MPDFSE.
A weak concentration (50 ppm or less) of sodium hypo-
chlorite solution is then substituted through the inside of
the MPDFSE, the supply lines, and the patient monitors
and maintained until the beginning of the cleaning process
prior to the next round of hemodialysis [19].
A concentration of 1 % acetic acid is also used to wash
the MPDFSE twice a week, following the above process,
in order to preventing calcium carbonate scaling inside
the equipment and pipes due to the dialysis fluid. In such
cases, the sterilization process first mentioned occurs after
cleaning with acetic acid.
Newly development of Fully automated dialysis
system (FADS)
The priming, guiding of blood into the dialyzer, and
blood rinse back for hemodialysis treatment require a
certain level of expertise which has proven to be a stum-
bling block to the development of automation. A system
utilizing backfiltrated dialysis fluid or substitution fluidFig. 4 Fully automated dialysis system (FADS) a Automated guiding of blo
indicate the flow of the dialysate. Thick blue arrows indicate the direction o
flow of blood, and blue lines indicate the flow of the dialysate. Thick blue aby online process as a means of standardizing and reducing
the labor involved in these processes has thus been de-
veloped [18–20]. These systems makes active use of the
backfiltrated dialysis fluid or substitution fluid by on-
line process and requires strict control of water quality
for each patient monitor and the CDDS, as well as
purification of the dialysis fluid.
The FADS was able to actively use purified dialysis
fluid through backfiltration or substitution fluid to auto-
mate the priming, blood rinse back, and rapid fluid re-
plenishment processes, with each process segueing to
the next through the touch of a single button (Fig. 4).
The advantages of the FADS in clinical terms are the
shortened time required for start-up and blood rinse
back and the simplification of action needed for rapid
fluid replenishment, rendering hemodialysis operable by
staff, regardless of their level of experience. This equip-
ment also allows the separation of duties for needle in-
sertion/removal and startup/blood rinse back, so that
dialysis staff with long experience can handle the needle
insertion/removal while staff with less experience can han-
dle startup/blood rinse back. This can reduce the number
of staff needed for each dialysis session and saves on labor
costs [18, 19]. The hermetically sealed nature of the blood
circuit, from needle insertion to the end of hemodialysis
treatment, has also reduced the risk of incidents involving
air bubbles or blood contamination. Human errors are
minimized through the simplification of the processes
involved in hemodialysis treatment. The number of acci-
dents reported that have occurred due to less experienced
staff has decreased since the introduction of the FADS.
Conclusions
CDDS has been used exclusively in Japan since 1960s.
Approximately 88 % of dialysis machines are patient
monitors with CDDS. It is a cost-effective, laborsaving,
time-tested system with a good microbial safety profile,od into the dialyzer. Red lines indicate the flow of blood. Blue lines
f dialysate flow. b Blood return and collection. Red lines indicate the
rrows indicate the direction of the dialysate flow
Kawanishi et al. Renal Replacement Therapy  (2016) 2:1 Page 8 of 8which has been defined from 45 years of experience. In
many countries, especially in Asia, the number of ESRD
patients is increasing [2]. The CDDS will contribute to
such emerging situations with its easy handling and
economic advantages.
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